cinacalcet aristo 30 mg
aristo pharma gmbh - cinacalcethydroklorid - tablett, filmdrasjert - 30 mg
cinacalcet aristo 60 mg
aristo pharma gmbh - cinacalcethydroklorid - tablett, filmdrasjert - 60 mg
cinacalcet aristo 90 mg
aristo pharma gmbh - cinacalcethydroklorid - tablett, filmdrasjert - 90 mg
forsteo 20 mikrog/80 mikroliter
paranova as - teriparatid - injeksjonsvæske, oppløsning i ferdigfylt penn - 20 mikrog/80 mikroliter
trulicity 1.5 mg
2care4 aps - dulaglutid - injeksjonsvæske, oppløsning - 1.5 mg
humalog kwikpen 200 e/ ml
2care4 aps - insulin lispro - injeksjonsvæske, oppløsning i ferdigfylt penn - 200 e/ ml
trulicity 3 mg
orifarm as - dulaglutid - injeksjonsvæske, oppløsning - 3 mg
trulicity 4.5 mg
orifarm as - dulaglutid - injeksjonsvæske, oppløsning - 4.5 mg
xultophy 100 e/ ml / 3.6 mg/ ml
2care4 aps - insulin degludek / liraglutid - injeksjonsvæske, oppløsning i ferdigfylt penn - 100 e/ ml / 3.6 mg/ ml
cevenfacta
laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemoragika - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.